ClinicalTrials.gg
CompletedNCT04686838READyR-IIUpdated Jan 18, 2023

REmote Assessment and Dynamic Response Intervention II

An interventional study of READyR II: A and READyR II: B in Dementia, Alzheimer Disease and Relationship, Marital, sponsored by Oregon Health and Science University. Completed at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2023-01-18.

Sponsored by Oregon Health and Science University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

The purpose of the READyR II Study is to test a dynamic tailoring phase of a remote assessment for changing dementia-related care needs.

Read the detailed description

Unmet dementia-related care needs are highly prevalent, and are detrimental to the care dyad's (person with dementia and their family care partner) health, safety, mortality, and likelihood of nursing home placement. READyR II tests a dynamic tailoring phase of an intervention program that was previously developed to remotely assess dementia-related care needs using digital data on behavioral patterns (from sensors and wearables) in the home. READyR II follows participants who have completed READyR for a total of six months in order to detect anomalies in activity patterns that may indicate new and unforeseen care needs.

People who voluntarily decide to participate in this follow-up intervention study will be asked to continue participating with the in-home monitoring sensor platform, complete weekly questionnaires, and receive regular follow-up telephone calls from the study team.

02

Conditions studied

  • Dementia
  • Alzheimer Disease
  • Relationship, Marital
  • Caregiver Stress Syndrome

Keywords

  • Needs Assessment
  • Remote Monitoring
  • Technology
  • Care Values
  • Aging-in-Place
  • Family Caregiver
03

In context

Dementia

2,230 studies on the registry are indexed under Dementia; 549 are open to participants now.

This study's enrollment of 30 is below the median of 83 across 1,669 interventional studies indexed under Dementia.

Browse Dementia studies →

Lead sponsor

Oregon Health and Science University is the lead sponsor of 694 studies on the registry; 133 are open to participants now.

Of its 51 completed or terminated interventional studies of FDA-regulated products, 39 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • 62 years or older;
  • Able to identify a family care partner over age 20 who is living with you and will also consent to fully participate in the study
  • Probable or confirmed diagnosis of mild cognitive impairment or early-stage dementia
  • Age and education adjusted MOCA score > 15 (at most recent measurement by parent study) corresponding to early to moderate stage dementia

Exclusion Criteria:

  • Inability to speak English or read printed materials in English
  • Conditions that would limit participation at entry to study (e.g. visual or hearing impairments prohibiting reading and discussing the intervention materials)
  • Any uncontrolled medical condition that is expected to preclude completion of the study, such as late stage cancers

Family Care Partners

Inclusion:

  • 21 years or older;
  • Self-identifying as a family member and care partner residing with the PwD participant;

Exclusion:

  • Inability to speak English or read printed materials in English
  • Conditions that would limit participation at entry to study (e.g. visual or hearing impairments prohibiting reading and discussing the intervention materials);
  • Any uncontrolled medical condition that is expected to preclude completion of the study, such as late stage cancers.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    READyR II A

    Continuous monitoring will be conducted and analyzed for anomaly detection. Participants in this arm will receive contact phone call when a potential change in care needs is indicated by an anomaly.

    Behavioral: READyR II: A

  • Active comparator
    READyR II B (comparison)

    Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content. Standard educational content will instead be shared over the phone.

    Behavioral: READyR II: B

Interventions

  • BehavioralREADyR II: A

    Continuous monitoring for anomaly detection and contact phone call when a potential change in care needs is indicated by an anomaly.

  • BehavioralREADyR II: B

    Sensors will remain in the home but anomaly detection analysis will not be performed and contact phone calls will be at regular intervals without dynamic tailoring content.

06

What researchers measure

Primary outcomes

  1. Mean difference effect sizes for pre-post change the care dyad's preparation for future care needs

    The Preparation for Future Care Needs Scale (Short Form) assesses the degree to which an individual has engaged in planning for future care needs in late life using 15 items and 5 subscales representing distinct planning processes (awareness, gathering information, decision making, concrete planning, avoidance). Items are scored on a 5 point Likert scale with higher scores indicating greater preparation for future care needs. Sorensen, S., Chapman, B. P., Duberstein, P. R., Pinquart, M., \& Lyness, J. M. (2017). Assessing future care preparation in late life: Two short measures. Psychol Assess, 29(12), 1480-1495.

    Time frame: Baseline compared with 18 weeks

  2. Mean difference effect sizes for pre-post change in the care dyad's relationship quality

    The Dyadic Relationship Scale assesses the positive dyadic interactions and negative dyadic strain experienced by caregivers (11 items) and care recipients (10 items). Items are averaged for a summary score that ranges from 0 to 3, with higher scores indicating more positive interactions in the relationship, or more relationship strain, respectively. Sebern, M.D. \& Whitlatch, C.J. (2007). Dyadic Relationship Scale: A measure of the impact of the provision and receipt of family care. The Gerontologist, 47(6), 741-751.

    Time frame: Baseline compared with 18 weeks

  3. Mean difference effect sizes for pre-post change in the amount of incongruence between the care partner's understanding of the care values of the person with dementia

    The Care Values Scale assesses the importance of four care-related values to the person with dementia from the perspectives of the person with dementia and their care partner. Items for each of the four subscales are averaged for a summary score that ranges from 1 to 3, with higher scores indicating greater importance of the care value to the person with dementia. Miller LM, Whitlatch CJ, Lee CS, Caserta MS. Care Values in Dementia: Patterns of Perception and Incongruence Among Family Care Dyads. The Gerontologist. 2018.

    Time frame: Baseline compared with 18 weeks

Secondary outcomes

  1. Mean difference effect sizes for pre-post change in the amount of care-related strain reported

    Subjective strain from caregiving will be assessed among family care partners at baseline and follow-up assessments using the Zarit Burden Interview (ZBI), short-form (12 items). Scores range from 0-48 with higher scores indicating a greater degree of strain from providing care.

    Time frame: Baseline compared with 12 weeks

  2. Mean difference effect sizes for pre-post change in the care dyad's quality of life

    The Quality of Life: Alzheimer's Disease Scale assesses individual perceptions of quality of life (from poor to excellent) across 13 items. Items are averaged for a summary score of 1 to 4, higher scores indicating greater degree of quality of life. Logsdon, R. G., Gibbons, L. E., McCurry, S. M., \& Teri, L. (1999). Quality of Life in Alzheimer's Disease: Patient and Caregiver Reports. Journal of Mental Health and Aging, 5(1), 21-32.

    Time frame: Baseline compared with 18 weeks

  3. Mean difference effect sizes for pre-post change in the care dyad's concealment of emotions

    The Emotional Intimacy Disruptive Behavior Scale (8 items) assesses the frequency of engagement in behaviors to conceal emotions about an illness from one's partner. Druley, J. A., Stephens, M. A. P., \& Coyne, J. C. (1997). Emotional and physical intimacy in coping with Lupus: Women's dilemmas of disclosure and approach. Health Psychology, 16, 506-514.

    Time frame: Baseline compared with 18 weeks

Other outcomes

  1. Time spent out of the home

    Time spent out of home will be robustly and accurately measured through an algorithm using sensor (motion/contact) and actigraphy data. Petersen J, Austin D, Mattek N, Kaye J. Time Out-of-Home and Cognitive, Physical, and Emotional Wellbeing of Older Adults: A Longitudinal Mixed Effects Model. PloS one. 2015;10(10):e0139643.

    Time frame: Continuously over 18 weeks

  2. Physical activity / sedentary behavior

    Physical activity and sedentary bouts will be measured using actigraphy data.

    Time frame: Continuously over 18 weeks

  3. Time spent together / separate

    Time spent together/separate as a dyad will be observed through previously-developed algorithms using data from PIR motion/contact sensors and actigraphy. We will consider times when the informal care dyad is together in the same room, separate within/outside of the home, and time in bathroom together (indicating ADL dependency).

    Time frame: Continuously over 18 weeks

  4. Sleep patterns

    Sleep patterns be measured using actigraphy, motion sensors, and a bed mat sensor.

    Time frame: Continuously over 18 weeks

07

Study locations

1 site
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified IPD will be available upon request to our Alzheimer's Disease Research Center Supporting Information: Time Frame: Data will become available after completion of study and after publication of primary study aims. Access Criteria: Requests need to made to the PI at the Oregon Alzheimer's Disease Research Center (OARDC). A short data request form will need to be submitted to the OADRC.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04686838
Responsible party
Lyndsey Miller (Co-Principal Investigator, Oregon Health and Science University) — Principal investigator
First posted
Dec 29, 2020
Start date
Jul 1, 2021
Primary completion
Nov 17, 2022
Completion
Nov 25, 2022
Last update
Jan 18, 2023

Study contacts

Lyndsey M Miller, PhD
principal investigator · Oregon Health and Science University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion